Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 35 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsActive, not recruitingNCT03390504Phase 3Results posted
• OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03390296Phase 1/2Results posted
• METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatinCompletedNCT03388190Phase 2Results posted
• Survival Prolongation by Rationale Innovative GenomicsTerminatedNCT03386929Phase 1/2Results posted
• Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid TumorsTerminatedNCT03386721Phase 2Results posted
• SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung EffectsCompletedNCT03383302Phase 1/2Results posted
• Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT03382561Phase 2Results posted
• Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT03379259Phase 1/2Results posted
• An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCompletedNCT03377361Phase 1/2Results posted
• Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerActive, not recruitingNCT03377023Phase 1/2Results posted
• Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic AdenocarcinomaTerminatedNCT03376659Phase 1/2Results posted
• Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerCompletedNCT03373760Phase 2Results posted
• A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast CancerCompletedNCT03371017Phase 3Results posted
• Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaCompletedNCT03370276Phase 1/2Results posted
• A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsCompletedNCT03369223Phase 1/2Results posted
• Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical CancerTerminatedNCT03367871Phase 2Results posted
• A Single Dose of Pembrolizumab in HIV-Infected PeopleTerminatedNCT03367754Phase 1Results posted
• Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerActive, not recruitingNCT03367741Phase 2Results posted
• Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated GlioblastomaCompletedNCT03367715Phase 2Results posted
• Breast Cancer Study of Preoperative Pembrolizumab + RadiationActive, not recruitingNCT03366844Phase 1/2Results posted
• PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesCompletedNCT03365791Phase 2Results posted
• Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03358875Phase 3Results posted
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT03358719Phase 1Results posted
• Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)CompletedNCT03358472Phase 3Results posted
• A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03357952Phase 2/3Results posted
• Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive TherapyCompletedNCT03355560Phase 2Results posted
• Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck CancerCompletedNCT03349710Phase 3Results posted
• DPX-Survivac and Checkpoint Inhibitor in DLBCLCompletedNCT03349450Phase 2Results posted
• Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung CancerTerminatedNCT03348904Phase 3Results posted
• Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former SmokersActive, not recruitingNCT03347838Phase 2Results posted
• Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With GlioblastomaTerminatedNCT03347617Phase 2Results posted
• Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic CancerTerminatedNCT03344172Phase 2Results posted
• KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric CancerCompletedNCT03342937Phase 2Results posted
• Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by SurgeryCompletedNCT03342911Phase 2Results posted
• Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNActive, not recruitingNCT03341936Phase 2Results posted
• Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT03340766Phase 1Results posted
• Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue SarcomaCompletedNCT03338959Phase 1/2Results posted
• A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
• A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerCompletedNCT03336216Phase 2Results posted
• Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results posted
• Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03333746Phase 2Results posted
• Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal CancersCompletedNCT03332498Phase 1/2Results posted
• Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin LymphomaCompletedNCT03331341Phase 1/2Results posted
• Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid TumorsTerminatedNCT03330405Phase 1/2Results posted
• Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT03325816Phase 1/2Results posted
• Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain MetastasesTerminatedNCT03325166Phase 2Results posted
• Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable MelanomaTerminatedNCT03325101Phase 1/2Results posted
• Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of RecurrenceCompletedNCT03322267Phase 2Results posted
• A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line TherapiesCompletedNCT03321630Phase 2Results posted
• Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical CystectomyCompletedNCT03319745Phase 2Results posted
• Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced MalignanciesTerminatedNCT03317496Phase 1/2Results posted
• Study of Pembrolizumab and Radiotherapy in Liver CancerTerminatedNCT03316872Phase 2Results posted
• A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerCompletedNCT03316586Phase 2Results posted
• Pembrolizumab in Neoplasms or LymphomasSuspendedNCT03316573Phase 2Results posted
• Priming Immunotherapy in Advanced Disease With RadiationCompletedNCT03313804Phase 2Results posted
• A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaCompletedNCT03312530Phase 1/2Results posted
• Anti-PD-L1 and SAbR for Ovarian CancerTerminatedNCT03312114Phase 2Results posted
• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsTerminatedNCT03311334Phase 1/2Results posted
• Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT03310957Phase 1/2Results posted
• Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell LymphomaCompletedNCT03309878Phase 1/2Results posted
• Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedNCT03307785Phase 1Results posted
• Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung CarcinomaTerminatedNCT03307759Phase 1Results posted
• Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 TherapyTerminatedNCT03302247Phase 2Results posted
• Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)CompletedNCT03302234Phase 3Results posted
• A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic MelanomaTerminatedNCT03301636Phase 2Results posted
• Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene MutationsCompletedNCT03299088Phase 1Results posted
• Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingNCT03298451Phase 3Results posted
• Study of AMG 596 in Patients With EGFRvIII Positive GlioblastomaTerminatedNCT03296696Phase 1Results posted
• Adoptive Cell Therapy Across Cancer DiagnosesCompletedNCT03296137Phase 1/2Results posted
• BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing CystectomyCompletedNCT03294304Phase 2Results posted
• A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell CarcinomaCompletedNCT03294083Phase 1/2Results posted
• Pembrolizumab in Elderly Patients With Advanced Lung CancerCompletedNCT03293680Phase 2Results posted
• Epacadostat and Pembrolizumab in Patients With GISTTerminatedNCT03291054Phase 2Results posted
• Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine TumorsCompletedNCT03290079Phase 2Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)CompletedNCT03289533Phase 1Results posted
• Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial CarcinomaTerminatedNCT03287050Phase 2Results posted
• Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With PembrolizumabTerminatedNCT03286114Phase 1Results posted
• A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT03285763Phase 4Results posted
• Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)CompletedNCT03285321Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)CompletedNCT03284424Phase 2Results posted
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedNCT03281369Phase 1/2Results posted
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT03280563Phase 1/2Results posted
• Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade MeningiomaActive, not recruitingNCT03279692Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Combination With RomidepsinActive, not recruitingNCT03278782Phase 1/2Results posted
• Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell CarcinomaTerminatedNCT03278626Phase 1/2Results posted
• Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV MelanomaCompletedNCT03276832Early Phase 1Results posted
• Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRCCompletedNCT03274804Phase 1Results posted
• Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient TumorsCompletedNCT03274661Phase 2Results posted
• Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary CarcinomaTerminatedNCT03274258Phase 2Results posted
• A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type MelanomaTerminatedNCT03273153Phase 3Results posted
• Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial CancerTerminatedNCT03272217Phase 2Results posted
• Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS MutationCompletedNCT03271047Phase 2Results posted
• Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT03267888Phase 1/2Results posted
• Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)CompletedNCT03267498Phase 2Results posted
• Azacitidine and Pembrolizumab in Pancreatic CancerCompletedNCT03264404Phase 2Results posted
• A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid TumorsCompletedNCT03264066Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedNCT03260894Phase 3Results posted
• Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney CancerTerminatedNCT03260504Phase 1Results posted
• Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersActive, not recruitingNCT03260023Phase 1/2Results posted
• Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)CompletedNCT03258593Phase 1Results posted

← Immune Checkpoint Inhibitors overview